<DOC>
	<DOCNO>NCT00111683</DOCNO>
	<brief_summary>In study participant relapsed/refractory leukemia give MK-0457 sequential cohort vary treatment duration determine maximum tolerate dose ( MTD ) MK-0457 .</brief_summary>
	<brief_title>MK0457 Patients With Leukemia ( 0457-003 )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , B-Cell</mesh_term>
	<criteria>Part 1 : Patients relapsed/refractory acute myelogenous leukemia ( AML ) , poor risk myelodysplastic syndrome ( MDS ) , Bcell acute lymphocytic leukemia ( ALL ) , myeloproliferative disease , chronic myelogenous leukemia ( CML ) blast crisis Part 2 : Acute myelogenous leukemia ( FLT3 mutation ) , myeloproliferative disease At least 2 week since last cytotoxic therapy Acceptable renal hepatic function Ambulatory , capable selfcare , bed 50 % waking hour More 2 month since autologous bone marrow peripheral blood stem cell transplantation Not fully recover previous antileukemia therapy Previous allogeneic bone marrow transplant Uncontrolled congestive heart failure Myocardial infarction within last 3 month Active uncontrolled infection Pregnancy lactation Currently active second malignancy , nonmelanoma skin cancer History hepatitis B C , know HIV positivity , AIDS relate illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Myelodysplastic Syndrome [ Refractory Anemia</keyword>
	<keyword>Excess Blasts-1 2 ( WHO Classification ) ]</keyword>
	<keyword>Chronic Myelogenous Leukemia blast crisis</keyword>
</DOC>